Rising and Higher Healthcare Resource Utilization (HCRU) and Costs of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH) Patients with Advanced Liver Disease of Increasing Severity - Results of a US Real-World Analysis

被引:0
|
作者
Wong, Robert J. [1 ]
Kachru, Nandita [2 ]
Meyer, Nicole [3 ]
Gordon, Stuart C. [4 ]
机构
[1] Highland Hosp, Alameda Hlth Syst, Div Gastroenterol & Hepatol, Oakland, CA USA
[2] Gilead Sci, Foster City, CA USA
[3] Truven Hlth Analyt, Cambridge, MA USA
[4] Henry Ford Hlth Syst, Detroit, MI USA
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
2268
引用
收藏
页码:1283A / 1284A
页数:2
相关论文
共 50 条
  • [41] Therapeutic Effects of microRNAs on Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review and Meta-Analysis
    Zhu, Yuezhi
    Tan, Jen Kit
    Wong, Sok Kuan
    Goon, Jo Aan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (11)
  • [42] Prevalence and predictors of de novo nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) after orthotopic liver transplantation (OLT)
    Seo, Suk
    Maganti, Kalyani
    Khehra, Manjit
    Ramsamooj, Rajendra
    Tsodikov, Alexander
    Torok, Natalie
    GASTROENTEROLOGY, 2006, 130 (04) : A789 - A789
  • [43] Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients
    Gordon, Stuart C.
    Fraysse, Jeremy
    Li, Suying
    Ozbay, A. Burak
    Wong, Robert J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 (04): : 562 - 574
  • [44] Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): prevalence, therapeutic innovations, and stumbling blocks for clinical development
    Alkhouri, Naim
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (02) : 115 - 116
  • [45] EMPHASIZING DIVERSITY IN NONALCOHOLIC STEATOHEPATITIS (NASH) STUDIES: CHARACTERIZATION OF A NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) SCREENING DATABASE.
    Paglialunga, S.
    Jaycox, S.
    Kar, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S39 - S39
  • [46] Effect of Metformin on Ballooning Degeneration in Nonalcoholic Steatohepatitis (NASH): When to Use Metformin in Nonalcoholic Fatty Liver Disease (NAFLD)
    Doycheva, Iliana
    Loomba, Rohit
    ADVANCES IN THERAPY, 2014, 31 (01) : 30 - 43
  • [47] Effect of Metformin on Ballooning Degeneration in Nonalcoholic Steatohepatitis (NASH): When to Use Metformin in Nonalcoholic Fatty Liver Disease (NAFLD)
    Iliana Doycheva
    Rohit Loomba
    Advances in Therapy, 2014, 31 : 30 - 43
  • [48] Concomitance of nonalcoholic fatty liver disease/steatohepatitis (NAFLD/NASH) is associated with the histological severity in Hepatitis B virus-infected liver
    Aizawa, Nobuhiro
    Enomoto, Hirayuki
    Miyamoto, Yuho
    Ishii, Noriko
    Hasegawa, Kunihiro
    Yuri, Yukihisa
    Takata, Ryo
    Yoh, Kazunori
    Ishii, Akio
    Nakano, Chikage
    Sakai, Yoshiyuki
    Takashima, Tomoyuki
    Ikeda, Naoto
    Nishimura, Takashi
    Iwata, Yoshinori
    Nishikawa, Hiroki
    Iijima, Hiroko
    Nishiguchi, Shuhei
    HEPATOLOGY, 2016, 64 : 306A - 307A
  • [49] MRE-based NASH score for diagnosis of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease
    Young-Sun Lee
    Ji Eun Lee
    Hyon-Seung Yi
    Young Kul Jung
    Dae Won Jun
    Ji Hoon Kim
    Yeon Seok Seo
    Hyung Joon Yim
    Baek-hui Kim
    Jeong Woo Kim
    Chang Hee Lee
    Jong Eun Yeon
    Juneyoung Lee
    Soon Ho Um
    Kwan Soo Byun
    Hepatology International, 2022, 16 : 316 - 324
  • [50] MRE-based NASH score for diagnosis of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease
    Lee, Young-Sun
    Lee, Ji Eun
    Yi, Hyon-Seung
    Jung, Young Kul
    Jun, Dae Won
    Kim, Ji Hoon
    Seo, Yeon Seok
    Yim, Hyung Joon
    Kim, Baek-hui
    Kim, Jeong Woo
    Lee, Chang Hee
    Yeon, Jong Eun
    Lee, Juneyoung
    Um, Soon Ho
    Byun, Kwan Soo
    HEPATOLOGY INTERNATIONAL, 2022, 16 (02) : 316 - 324